SSYS Stock Analysis: Stratasys | NASDAQ
Computer Hardware | NASDAQ, USA | Market Cap: 484m USD | 12M Return: -38.3% | IL0011267213 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.06M
Qual. Beats: 1
Rev. Trend: -92.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Stratasys Ltd. (NASDAQ: SSYS) provides connected polymer-based 3D printing solutions spanning prototyping, tooling, and production parts. Its system portfolio includes FDM and PolyJet printers, industrial stereolithography (SLA) and SAF platforms, the Origin P3 printer line, and the J35 Pro multi-material desktop unit, alongside software such as GrabCAD and Titanium control software.
The company also supplies a broad range of resins and consumables, including GelMatrix, TissueMatrix, BoneMatrix, and Somos materials, with applications extending into dental (DentaJet), medical (Digital Anatomy Creator, Anatomy), and fashion (TechStyle) markets. Stratasys complements its hardware and materials with paid parts, professional services, and design-to-manufacturing support, and is headquartered in Minnetonka, Minnesota.
Stratasys operates in the industrial 3D printing sector, which typically follows an integrated razor-and-blade business model, generating recurring revenue from proprietary consumables, software, and services tied to its installed base of printers. The company is classified within Information Technology (Technology Hardware, Storage & Peripherals) and is listed on the U.S. NASDAQ exchange.
- Industrial 3D printer shipments decline on weak manufacturing capex
- Dental and medical 3D printing revenue growth drives margin expansion
- Competition from HP and desktop resin printers pressures average selling prices
| Net Income: -69.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -1.88 > 1.0 |
| NWC/Revenue: 71.60% < 20% (prev 78.09%; Δ -6.49% < -1%) |
| CFO/TA -0.01 > 3% & CFO -7.95m > Net Income -69.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.7m) vs 12m ago 3.03% < -2% |
| Gross Margin: 43.75% > 18% (prev 43.73%; Δ 0.02% > 0.5%) |
| Asset Turnover: 51.79% > 50% (prev 51.64%; Δ 0.15% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.38 (Total Current Assets 559.5m - Total Current Liabilities 163.6m) / Total Assets 1.05b |
| B: -2.36 (Retained Earnings -2.48b / Total Assets 1.05b) |
| C: -0.06 (EBIT TTM -67.8m / Avg Total Assets 1.07b) |
| D: 3.45 (Book Value of Equity 812.5m / Total Liabilities 235.5m) |
| Altman-Z'' = -2.03 = D |
| DSRI: 1.13 (Receivables 169.1m/151.3m, Revenue 552.9m/561.5m) |
| GMI: 1.00 (GM 43.73% / 43.75%) |
| AQI: 1.08 (AQ_t 0.26 / AQ_t-1 0.24) |
| SGI: 0.98 (Revenue 552.9m / 561.5m) |
| TATA: -0.06 (NI -69.8m - CFO -7.95m) / TA 1.05b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of November 22, 2026, the stock is trading at USD 5.06 with a total of 1,672,343 shares traded. Over the past week, the price has changed by -12.91%, over one month by -27.30%, over three months by -35.62% and over the past year by -38.29%.
Current recommended Stop Loss: 4.60 (which is 9.1% or 1.4 ATR below the current price).
Stratasys has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SSYS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9.7 | 91.1% |
P/E Forward = 30.1205
P/S = 0.8746
P/B = 0.6006
P/EG = 2.0632
Revenue TTM = 552.9m USD
EBIT TTM = -67.8m USD
EBITDA TTM = -23.0m USD
Long Term Debt = 19.8m USD (estimated: total debt 26.3m - short term 6.49m)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 26.3m USD (from shortLongTermDebtTotal, last quarter) (leases 26.3m already included)
Net Debt = -184.4m USD (calculated: Debt 26.3m - CCE 210.7m)
Enterprise Value = 299.2m USD (483.6m + Debt 26.3m - CCE 210.7m)
Interest Coverage Ratio = unknown (Ebit TTM -67.8m / Interest Expense TTM 0.0)
EV/FCF = -11.41x (Enterprise Value 299.2m / FCF TTM -26.2m)
FCF Yield = -8.76% (FCF TTM -26.2m / Enterprise Value 299.2m)
FCF Margin = -4.74% (FCF TTM -26.2m / Revenue TTM 552.9m)
Net Margin = -12.61% (Net Income TTM -69.8m / Revenue TTM 552.9m)
Gross Margin = 43.75% ((Revenue TTM 552.9m - Cost of Revenue TTM 311.0m) / Revenue TTM)
Gross Margin QoQ = 44.15% (prev 42.39%)
Tobins Q-Ratio = 0.29 (Enterprise Value 299.2m / Total Assets 1.05b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 26.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -53.6m (EBIT -67.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.42 (Total Current Assets 559.5m / Total Current Liabilities 163.6m)
Debt / Equity = 0.03 (Debt 26.3m / totalStockholderEquity, last quarter 812.5m)
Debt / EBITDA = 8.00 (negative EBITDA) (Net Debt -184.4m / EBITDA -23.0m)
Debt / FCF = 7.03 (negative FCF - burning cash) (Net Debt -184.4m / FCF TTM -26.2m)
Total Stockholder Equity = 824.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.53% (Net Income -69.8m / Total Assets 1.05b)
RoE = -8.46% (Net Income TTM -69.8m / Total Stockholder Equity 824.9m)
RoCE = -8.03% (EBIT -67.8m / Capital Employed (Equity 824.9m + L.T.Debt 19.8m))
RoIC = -6.21% (negative operating profit) (NOPAT -53.6m / Invested Capital 863.2m)
WACC = 11.77% (E(483.6m)/V(509.9m) * Re(12.41%) + D(26.3m)/V(509.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.86 | Cagr: 10.04%
[DCF] Fair Price = unknown (Cash Flow -26.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.85 | # QB: 1
Revenue Correlation: -92.08 | Revenue CAGR: -4.77% | SUE: 1.12 | # QB: 1
EPS current Quarter (2027-03-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.10 | Chg30d=-6.82% | Revisions=-29% | GrowthEPS=-31.7% | GrowthRev=+1.4%
EPS next Year (2027-12-31): EPS=0.12 | Chg30d=-36.00% | Revisions=+40% | GrowthEPS=+17.1% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +0% (up=3, down=3)